The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome
Alejandro Aruffo(University of Washington Medical Center), Hans D. Ochs(Infectious Disease Research Institute), Diane Hollenbaugh(Neoleukin Therapeutics (United States)), Jürgen Bajorath(University of Bonn), Mary Farrington(University of Washington Medical Center), Shigeaki Nonoyama(National Defense Medical College), R J Noelle, Athena Milatovich(Stanford Medicine), Xu Li(Howard Hughes Medical Institute), Uta Francke(Stanford University), J A Ledbetter(Bristol-Myers Squibb (Germany)), Michael Neubauer(Bristol-Myers Squibb (United States)), Laura S. Grosmaire(Bristol-Myers Squibb (United States)), Robert L. Roberts(UCLA Medical Center), Ronald E. Stenkamp(University of Washington)
Cited by 824
Related Papers
Docking and scoring in virtual screening for drug discovery: methods and applications
|Nature Reviews Drug Discovery|2004|4k
The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3
|Nature Genetics|2001|3.4k
Chronic Granulomatous Disease: Report on a National Registry of 368 Patients
|Medicine|2000|1.7k
CTLA-4 is a second receptor for the B cell activation antigen B7.
|The Journal of Experimental Medicine|1991|1.7k
Polypharmacology: Challenges and Opportunities in Drug Discovery
|Journal of Medicinal Chemistry|2014|1.1k